| Previous Close | 34.20 |
| Open | 34.29 |
| Bid | 34.47 x 1200 |
| Ask | 34.43 x 3200 |
| Day's Range | 33.96 - 34.55 |
| 52 Week Range | 26.45 - 43.08 |
| Volume | 30,561,785 |
| Avg. Volume | 39,909,840 |
| Market Cap | 191.815B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 20.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (4.54%) |
| Ex-Dividend Date | Jan. 28, 2021 |
| 1y Target Est | N/A |
- Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 1:15 p.m. Eastern Standard Time.
- Business Wire
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test. The FDA action also converts the 2018 accelerated approval to full approval. The application was approved under the FDA’s Real-Time Oncology Review (RTOR) pilot program.
- Business Wire
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. With the MAA acceptance, the formal review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) begins.
